Logo image
Clinical Utility of Circulating Tumor Cells for Predicting Major Histopathological Response after Neoadjuvant Chemoradiotherapy in Patients with Esophageal Cancer
期刊文章   同儕審查

Clinical Utility of Circulating Tumor Cells for Predicting Major Histopathological Response after Neoadjuvant Chemoradiotherapy in Patients with Esophageal Cancer

Xing Gao, Osbert Qi-Yao Leow, Chien-Hung Chiu, Ming-Mo Hou, Jason Chia-Hsun Hsieh 和 Yin-Kai Chao
Journal of personalized medicine, 卷.12(9), 頁.1440
31/08/2022
PMID: 36143225
Web of Science ID: WOS:000856704700001

摘要

General & Internal Medicine Health Care Sciences & Services Life Sciences & Biomedicine Medicine, General & Internal Science & Technology
Background: A "surgery as needed" approach may be offered to patients with esophageal cancer (EC) who achieve major histopathological response (MaHR) after neoadjuvant chemoradiotherapy (nCRT). However, the utility of clinical response assessment (CRE) for predicting histopathological response to nCRT remains limited. Circulating tumor cells (CTCs) hold promise as biomarkers of response to nCRT. Methods: We analyzed the clinical utility of post-nCRT CTCs, alone or in combination with CRE, in the prediction of MaHR. We defined MaHR as either the lack or a limited presence (<= 10%) of vital residual tumor cells in the resected esophageal specimen in the absence of nodal involvement. Results: Of the 48 study patients, 27 (56%) achieved MaHR. Patients with MaHR had a significantly lower CTCs count compared with those without (3.61 +/- 4.53 versus 6.83 +/- 5.22 per mL of blood, respectively; P = 0.027). Using a cutoff for positivity of 5 CTCs per mL of blood, the combination of CTCs and CRE allowed achieving a negative predictive value for MaHR of 93% (95% confidence interval [CI] = 70-99%) along with a false negative rate of 5% (95% CI = 1-33%). Conclusion: CTCs count assessed in combination with CRE can potentially help identify patients with EC who achieved MaHR after nCRT.

檔案與連結 (1)

url
https://doi.org/10.3390/jpm12091440檢視
已出版(紀錄版本) 開放

相關連結

詳細資料

Logo image